Lessons from immuno-oncology: A new era for cancer nanomedicine?

Nature Reviews Drug Discovery

Volumn 16, Issue 6, 2017, Pages 369-370

  Jiang, Wen ^a   Yuan, Hengfeng ^b,c   Chan, Charles K ^d   Von Roemeling, Christina A ^c   Yan, Zuoqin ^b   Weissman, Irving L ^d,e   Kim, Betty Y S ^c  

^a UNIVERSITY OF TEXAS   (United States)

^b FUDAN UNIVERSITY   (China)

^c MAYO CLINIC   (United States)

^d Institute for Stem Cell Biology and Regenerative Medicine and   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER IMMUNOTHERAPY; CANCER NANOMEDICINE; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNO NANOMEDICINE; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; MOLECULARLY TARGETED THERAPY; NANOMEDICINE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASMS; PROCEDURES; TRANSLATIONAL RESEARCH;

ANIMALS; DRUG DESIGN; HUMANS; IMMUNOTHERAPY; NANOMEDICINE; NEOPLASMS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85015629143     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd.2017.34     Document Type: Review

References (5)

1. Shi. J., Kantoff, P. W., Wooster, R. & Farokhzad, O. C. Cancer nanomedicine: progress, challenges and opportunities. Nat. Rev. Cancer 17, 20-37 (2017 ).
2. Wilhelm, S. et al. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 1,16014 (2016).
3. Lammers, T. et al. Cancer nanomedicine: is targeting our target? Nat. Rev. Mater. 1,16076 (2016).
4. Jiang, W. et al. Designing nanomedicine for immuno-oncology. Nat. Biomed. Eng. 0029 (2017).
5. Kranz, L. M. et al. Systemic RNA delivery to dendritic cells exploits antiviral defense for cancer immunotherapy. Nature 534, 396-401 (2016).